First published: 11th July 2023
We are delighted to announce that Cumulus Neuroscience will present interim data from our CNS-101 study at the Alzheimer’s Association International Conference 2023 in Amsterdam, Netherlands. The study is being conducted in collaboration with the University of Cambridge and Trinity Biomedical Science Institute.
Titled "Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia," the poster was accepted by the AAIC Scientific Program Committee.
"We are deeply grateful to the study participants and collaborators who dedicate their time with the hope of better understanding this life-changing neurodegenerative disease and accelerating much needed new treatments."
Brian Murphy, Ph.D.
CSO, Cumulus Neuroscience
“Today, traditional biomarkers are effective in tracking disease progression in clinical studies, however these do not scale to support large real-world studies, require patients to attend clinic appointments which are costly and can be inconvenient and stressful for patients,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Digital biomarkers have proven to be scalable, however, to date they have lacked objectivity and grounding in clinical measures. We are deeply grateful to the study participants and collaborators who dedicate their time with the hope of better understanding this life-changing neurodegenerative disease and accelerating much needed new treatments.”
Alzheimer's is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. Currently, there is no known cure for Alzheimer’s.
Cumulus poster presentation details are as follows:
Technology and Dementia Preconference- Title: TECH-P-108 "Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia "
- Date & Time: Saturday, July 15, 2023: 7:00 AM – 5:00 PM CEST
- Poster Number: 82187
- Session: Technology and Dementia Posters
- Title: P2-295 "Feasibility of real-world endpoints of functional neurophysiology in Alzheimer’s disease dementia"
- Date & Time: Monday, July 17, 2023: 8:45 AM – 4:15 PM CEST
- Poster Number: 78914
- Session p2-06: Biomarkers: Biomarkers (non-neuroimaging)
A second co-authored poster with Cumulus and Boston University was also accepted, titled “Feasibility of implementing wearable technologies for in-home assessment of behavioral and event-related potential responses after sleep and wakefulness in Alzheimer’s disease.”